(Photo: Mart Production)
Senate Bill 4220 is moving through Congress with bipartisan backing, seeking to prepare the VA to deliver emerging medical treatments to Veterans as soon as they receive federal approval.
Introduced on March 26, the proposal would establish an Office of Novel Therapeutics within the Veterans Health Administration to evaluate, guide, and implement new forms of care. This will create a more direct path between medical innovation and patient access.
The bill is sponsored by Sen. Tim Sheehy (R-Mont.) and co-sponsored by Sen. Ruben Gallego (D-Ariz.), Sen. Tammy Duckworth (D-Ill.), and Sen. John Boozman (D-Ark.). Supporters say the current system can lag behind advancements in medicine, leaving Veterans waiting years for treatments that are already available in other healthcare settings.
Much of the urgency surrounding SB 4220 comes from growing interest in alternative therapies, including psychedelic-assisted treatments that are currently under federal review. Early clinical research has shown potential in treating PTSD and other mental health conditions, particularly for patients who have not responded to standard medications or therapy. While these treatments are not yet widely available, lawmakers want the VA prepared to respond once regulatory decisions are made.
Support has also come from Veteran advocacy groups, including Iraq and Afghanistan Veterans of America and Disabled American Veterans. These organizations have raised concerns about gaps in treatment options, especially for PTSD, depression, and traumatic brain injuries, or TBI.
The legislation focuses on building the internal framework needed before new therapies become widely available. That includes setting clinical standards, training providers, establishing safety protocols, and coordinating research efforts across the VA system. By putting these pieces in place early, the department would be in a position to act quickly once treatments receive FDA approval.
Lawmakers behind the bill have stated that the VA has often taken longer than the private sector to adopt new treatments. Without a centralized structure, the process can be fragmented, with different facilities moving at different speeds. The proposed office would serve as a dedicated hub to align those efforts and reduce delays that can impact care.
If enacted, the bill would also support collaboration between the VA, academic institutions, and private research organizations. That coordination could help expand clinical trials involving Veterans and improve the overall understanding of how these therapies perform in real-world settings.
The bill is now under consideration in the Senate Committee on Veterans’ Affairs. As it moves through the legislative process, discussions are expected to continue around oversight, safety, and how the VA balances innovation with patient protection.
Author: Rikki Almanza
Rikki is a Web Content Coordinator for the American Legion, Department of California. With a deep-rooted family connection to the military, Rikki is committed to using her skills and knowledge to provide valuable assistance and resources to servicemembers and veterans.
